|
1
|
Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu
XY, Shen Z and Song YH: Inflammasomes as therapeutic targets in
human diseases. Signal Transduct Target Ther. 6:2472021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duncan JA, Bergstralh DT, Wang Y,
Willingham SB, Ye Z, Zimmermann AG and Ting JP: Cryopyrin/NALP3
binds ATP/dATP, is an ATPase, and requires ATP binding to mediate
inflammatory signaling. Proc Natl Acad Sci USA. 104:8041–8046.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jo EK, Kim JK, Shin DM and Sasakawa C:
Molecular mechanisms regulating NLRP3 inflammasome activation. Cell
Mol Immunol. 13:148–159. 2016. View Article : Google Scholar :
|
|
4
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: Molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozaki E, Campbell M and Doyle SL:
Targeting the NLRP3 inflammasome in chronic inflammatory diseases:
Current perspectives. J Inflamm Res. 8:15–27. 2015.PubMed/NCBI
|
|
6
|
Leemans JC, Cassel SL and Sutterwala FS:
Sensing damage by the NLRP3 inflammasome. Immunol Rev. 243:152–162.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schroder K, Zhou R and Tschopp J: The
NLRP3 inflammasome: A sensor for metabolic danger? Science.
327:296–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inoue M and Shinohara ML: NLRP3
Inflammasome and MS/EAE. Autoimmune Dis. 2013:8591452013.PubMed/NCBI
|
|
9
|
Zhen Y and Zhang H: NLRP3 inflammasome and
inflammatory bowel disease. Front Immunol. 10:2762019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelley N, Jeltema D, Duan Y and He Y: The
NLRP3 inflammasome: An overview of mechanisms of activation and
regulation. Int J Mol Sci. 20:33282019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J and Núñez G: The NLRP3 inflammasome:
Activation and regulation. Trends Biochem Sci. 48:331–344. 2023.
View Article : Google Scholar
|
|
12
|
Paik S, Kim JK, Silwal P, Sasakawa C and
Jo EK: An update on the regulatory mechanisms of NLRP3 inflammasome
activation. Cell Mol Immunol. 18:1141–1160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muñoz-Planillo R, Kuffa P, Martínez-Colón
G, Smith BL, Rajendiran TM and Núñez G: K+ efflux is the
common trigger of NLRP3 inflammasome activation by bacterial toxins
and particulate matter. Immunity. 38:1142–1153. 2013. View Article : Google Scholar
|
|
14
|
Xu Z, Chen ZM, Wu X, Zhang L, Cao Y and
Zhou P: Distinct molecular mechanisms underlying potassium efflux
for NLRP3 inflammasome activation. Front Immunol. 11:6094412020.
View Article : Google Scholar
|
|
15
|
Groß CJ, Mishra R, Schneider KS, Médard G,
Wettmarshausen J, Dittlein DC, Shi H, Gorka O, Koenig PA, Fromm S,
et al: K(+) efflux-independent NLRP3 inflammasome activation by
small molecules targeting mitochondria. Immunity. 45:761–773. 2016.
View Article : Google Scholar
|
|
16
|
Sanman LE, Qian Y, Eisele NA, Ng TM, van
der Linden WA, Monack DM, Weerapana E and Bogyo M: Disruption of
glycolytic flux is a signal for inflammasome signaling and
pyroptotic cell death. Elife. 5:e136632016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rajamäki K, Nordström T, Nurmi K, Åkerman
KE, Kovanen PT, Öörni K and Eklund KK: Extracellular acidosis is a
novel danger signal alerting innate immunity via the NLRP3
inflammasome. J Biol Chem. 288:13410–13419. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chae BJ, Lee KS, Hwang I and Yu JW:
Extracellular acidification augments NLRP3-mediated inflammasome
signaling in macrophages. Immune Netw. 23:e232023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee GS, Subramanian N, Kim AI,
Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner
DL and Chae JJ: The calcium-sensing receptor regulates the NLRP3
inflammasome through Ca2+ and cAMP. Nature. 492:123–127. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brough D, Le Feuvre RA, Wheeler RD,
Solovyova N, Hilfiker S, Rothwell NJ and Verkhratsky A: Ca2+ stores
and Ca2+ entry differentially contribute to the release of IL-1
beta and IL-1 alpha from murine macrophages. J Immunol.
170:3029–3036. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feldmeyer L, Keller M, Niklaus G, Hohl D,
Werner S and Beer HD: The inflammasome mediates UVB-induced
activation and secretion of interleukin-1beta by keratinocytes.
Curr Biol. 17:1140–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chu J, Thomas LM, Watkins SC, Franchi L,
Núñez G and Salter RD: Cholesterol-dependent cytolysins induce
rapid release of mature IL-1beta from murine macrophages in a NLRP3
inflammasome and cathepsin B-dependent manner. J Leukoc Biol.
86:1227–1238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katsnelson MA, Rucker LG, Russo HM and
Dubyak GR: K+ efflux agonists induce NLRP3 inflammasome activation
independently of Ca2+ signaling. J Immunol. 194:3937–3952. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang T, Lang X, Xu C, Wang X, Gong T, Yang
Y, Cui J, Bai L, Wang J, Jiang W and Zhou R: CLICs-dependent
chloride efflux is an essential and proximal upstream event for
NLRP3 inflammasome activation. Nat Commun. 8:2022017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verhoef PA, Kertesy SB, Lundberg K,
Kahlenberg JM and Dubyak GR: Inhibitory effects of chloride on the
activation of caspase-1, IL-1beta secretion, and cytolysis by the
P2X7 receptor. J Immunol. 175:7623–7634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mayes-Hopfinger L, Enache A, Xie J, Huang
CL, Köchl R, Tybulewicz VLJ, Fernandes-Alnemri T and Alnemri ES:
Chloride sensing by WNK1 regulates NLRP3 inflammasome activation
and pyroptosis. Nat Commun. 12:45462021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Green JP, Yu S, Martín-Sánchez F, Pelegrin
P, Lopez-Castejon G, Lawrence CB and Brough D: Chloride regulates
dynamic NLRP3-dependent ASC oligomerization and inflammasome
priming. Proc Natl Acad Sci USA. 115:E9371–E9380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou R, Yazdi AS, Menu P and Tschopp J: A
role for mitochondria in NLRP3 inflammasome activation. Nature.
469:221–225. 2011. View Article : Google Scholar
|
|
29
|
Dominic A, Le NT and Takahashi M: Loop
between NLRP3 inflammasome and reactive oxygen species. Antioxid
Redox Signal. 36:784–796. 2022. View Article : Google Scholar
|
|
30
|
Shimada K, Crother TR, Karlin J, Dagvadorj
J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, et
al: Oxidized mitochondrial DNA activates the NLRP3 inflammasome
during apoptosis. Immunity. 36:401–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iyer SS, He Q, Janczy JR, Elliott EI,
Zhong Z, Olivier AK, Sadler JJ, Knepper-Adrian V, Han R, Qiao L, et
al: Mitochondrial cardiolipin is required for Nlrp3 inflammasome
activation. Immunity. 39:311–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Halle A, Hornung V, Petzold GC, Stewart
CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ and
Golenbock DT: The NALP3 inflammasome is involved in the innate
immune response to amyloid-beta. Nat Immunol. 9:857–865. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lima H Jr, Jacobson LS, Goldberg MF,
Chandran K, Diaz-Griffero F, Lisanti MP and Brojatsch J: Role of
lysosome rupture in controlling Nlrp3 signaling and necrotic cell
death. Cell Cycle. 12:1868–1878. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schorn C, Frey B, Lauber K, Janko C,
Strysio M, Keppeler H, Gaipl US, Voll RE, Springer E, Munoz LE, et
al: Sodium overload and water influx activate the NALP3
inflammasome. J Biol Chem. 286:35–41. 2011. View Article : Google Scholar :
|
|
35
|
Hornung V, Bauernfeind F, Halle A, Samstad
EO, Kono H, Rock KL, Fitzgerald KA and Latz E: Silica crystals and
aluminum salts activate the NALP3 inflammasome through phagosomal
destabilization. Nat Immunol. 9:847–856. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dostert C, Guarda G, Romero JF, Menu P,
Gross O, Tardivel A, Suva ML, Stehle JC, Kopf M, Stamenkovic I, et
al: Malarial hemozoin is a Nalp3 inflammasome activating danger
signal. PLoS One. 4:e65102009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Orlowski GM, Colbert JD, Sharma S, Bogyo
M, Robertson SA and Rock KL: Multiple cathepsins promote Pro-IL-1β
synthesis and NLRP3-mediated IL-1β activation. J Immunol.
195:1685–1697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kayagaki N, Stowe IB, Lee BL, O'Rourke K,
Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT,
et al: Caspase-11 cleaves gasdermin D for non-canonical
inflammasome signalling. Nature. 526:666–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kayagaki N, Warming S, Lamkanfi M, Vande
Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al:
Non-canonical inflammasome activation targets caspase-11. Nature.
479:117–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li
P, Hu L and Shao F: Inflammatory caspases are innate immune
receptors for intracellular LPS. Nature. 514:187–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ding J, Wang K, Liu W, She Y, Sun Q, Shi
J, Sun H, Wang DC and Shao F: Pore-forming activity and structural
autoinhibition of the gasdermin family. Nature. 535:111–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ramirez MLG, Poreba M, Snipas SJ, Groborz
K, Drag M and Salvesen GS: Extensive peptide and natural protein
substrate screens reveal that mouse caspase-11 has much narrower
substrate specificity than caspase-1. J Biol Chem. 293:7058–7067.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gaidt MM, Ebert TS, Chauhan D, Schmidt T,
Schmid-Burgk JL, Rapino F, Robertson AA, Cooper MA, Graf T and
Hornung V: Human monocytes engage an alternative inflammasome
pathway. Immunity. 44:833–846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang L and Hauenstein AV: The NLRP3
inflammasome: Mechanism of action, role in disease and therapies.
Mol Aspects Med. 76:1008892020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He Y, Franchi L and Núñez G: TLR agonists
stimulate Nlrp3-dependent IL-1β production independently of the
purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol.
190:334–339. 2013. View Article : Google Scholar
|
|
46
|
Wang C, Zhou J, Wang J, Li S, Fukunaga A,
Yodoi J and Tian H: Progress in the mechanism and targeted drug
therapy for COPD. Signal Transduct Target Ther. 5:2482020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Birrell MA and Eltom S: The role of the
NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol
Ther. 130:364–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cicko S, Lucattelli M, Müller T,
Lommatzsch M, De Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R,
Dürk T, et al: Purinergic receptor inhibition prevents the
development of smoke-induced lung injury and emphysema. J Immunol.
185:688–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
De Nardo D, De Nardo CM and Latz E: New
insights into mechanisms controlling the NLRP3 inflammasome and its
role in lung disease. Am J Pathol. 184:42–54. 2014. View Article : Google Scholar :
|
|
50
|
Hosseinian N, Cho Y, Lockey RF and
Kolliputi N: The role of the NLRP3 inflammasome in pulmonary
diseases. Ther Adv Respir Dis. 9:188–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pauwels NS, Bracke KR, Dupont LL, Van
Pottelberge GR, Provoost S, Vanden Berghe T, Vandenabeele P,
Lambrecht BN, Joos GF and Brusselle GG: Role of IL-1α and the
Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary
inflammation and COPD. Eur Respir J. 38:1019–1028. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hoshino T, Kato S, Oka N, Imaoka H,
Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K,
et al: Pulmonary inflammation and emphysema: Role of the cytokines
IL-18 and IL-13. Am J Respir Crit Care Med. 176:49–62. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Churg A, Zhou S, Wang X, Wang R and Wright
JL: The role of interleukin-1beta in murine cigarette smoke-induced
emphysema and small airway remodeling. Am J Respir Cell Mol Biol.
40:482–490. 2009. View Article : Google Scholar
|
|
54
|
Eltom S, Stevenson CS, Rastrick J, Dale N,
Raemdonck K, Wong S, Catley MC, Belvisi MG and Birrell MA: P2X7
receptor and caspase 1 activation are central to airway
inflammation observed after exposure to tobacco smoke. PLoS One.
6:e240972011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu S, Panettieri RA Jr and Jude J:
Metabolomics in asthma: A platform for discovery. Mol Aspects Med.
85:1009902022. View Article : Google Scholar :
|
|
56
|
Müller T, Vieira RP, Grimm M, Dürk T,
Cicko S, Zeiser R, Jakob T, Martin SF, Blumenthal B, Sorichter S,
et al: A potential role for P2X7R in allergic airway inflammation
in mice and humans. Am J Respir Cell Mol Biol. 44:456–464. 2011.
View Article : Google Scholar
|
|
57
|
Yazdi AS, Guarda G, Riteau N, Drexler SK,
Tardivel A, Couillin I and Tschopp J: Nanoparticles activate the
NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause
pulmonary inflammation through release of IL-1α and IL-1β. Proc
Natl Acad Sci USA. 107:19449–19454. 2010. View Article : Google Scholar
|
|
58
|
Ather JL, Ckless K, Martin R, Foley KL,
Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC and
Poynter ME: Serum amyloid A activates the NLRP3 inflammasome and
promotes Th17 allergic asthma in mice. J Immunol. 187:64–73. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Idzko M, Hammad H, van Nimwegen M, Kool M,
Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di
Virgilio F, et al: Extracellular ATP triggers and maintains
asthmatic airway inflammation by activating dendritic cells. Nat
Med. 13:913–919. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nakae S, Komiyama Y, Yokoyama H, Nambu A,
Umeda M, Iwase M, Homma I, Sudo K, Horai R, Asano M and Iwakura Y:
IL-1 is required for allergen-specific Th2 cell activation and the
development of airway hypersensitivity response. Int Immunol.
15:483–490. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang CC, Fu CL, Yang YH, Lo YC, Wang LC,
Chuang YH, Chang DM and Chiang BL: Adenovirus expressing
interleukin-1 receptor antagonist alleviates allergic airway
inflammation in a murine model of asthma. Gene Ther. 13:1414–1421.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Harada M, Obara K, Hirota T, Yoshimoto T,
Hitomi Y, Sakashita M, Doi S, Miyatake A, Fujita K, Enomoto T, et
al: A functional polymorphism in IL-18 is associated with severity
of bronchial asthma. Am J Respir Crit Care Med. 180:1048–1055.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Luo W, Hu J, Xu W and Dong J: Distinct
spatial and temporal roles for Th1, Th2, and Th17 cells in asthma.
Front Immunol. 13:9740662022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Besnard AG, Guillou N, Tschopp J, Erard F,
Couillin I, Iwakura Y, Quesniaux V, Ryffel B and Togbe D: NLRP3
inflammasome is required in murine asthma in the absence of
aluminum adjuvant. Allergy. 66:1047–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Eisenbarth SC, Colegio OR, O'Connor W,
Sutterwala FS and Flavell RA: Crucial role for the Nalp3
inflammasome in the immunostimulatory properties of aluminium
adjuvants. Nature. 453:1122–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Demento SL, Eisenbarth SC, Foellmer HG,
Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig
E, Flavell RA and Fahmy TM: Inflammasome-activating nanoparticles
as modular systems for optimizing vaccine efficacy. Vaccine.
27:3013–3021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sawada M, Kawayama T, Imaoka H, Sakazaki
Y, Oda H, Takenaka S, Kaku Y, Azuma K, Tajiri M, Edakuni N, et al:
IL-18 induces airway hyperresponsiveness and pulmonary inflammation
via CD4+ T cell and IL-13. PLoS One. 8:e546232013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yamagata S, Tomita K, Sato R, Niwa A,
Higashino H and Tohda Y: Interleukin-18-deficient mice exhibit
diminished chronic inflammation and airway remodelling in
ovalbumin-induced asthma model. Clin Exp Immunol. 154:295–304.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Allen IC, Jania CM, Wilson JE, Tekeppe EM,
Hua X, Brickey WJ, Kwan M, Koller BH, Tilley SL and Ting JP:
Analysis of NLRP3 in the development of allergic airway disease in
mice. J Immunol. 188:2884–2893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hartwig C, Tschernig T, Mazzega M, Braun A
and Neumann D: Endogenous IL-18 in experimentally induced asthma
affects cytokine serum levels but is irrelevant for clinical
symptoms. Cytokine. 42:298–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Leung CC, Yu IT and Chen W: Silicosis.
Lancet. 379:2008–2018. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cassel SL, Eisenbarth SC, Iyer SS, Sadler
JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA and
Sutterwala FS: The Nalp3 inflammasome is essential for the
development of silicosis. Proc Natl Acad Sci USA. 105:9035–9040.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jessop F, Hamilton RF, Rhoderick JF, Shaw
PK and Holian A: Autophagy deficiency in macrophages enhances NLRP3
inflammasome activity and chronic lung disease following silica
exposure. Toxicol Appl Pharmacol. 309:101–110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tong SY, Davis JS, Eichenberger E, Holland
TL and Fowler VG Jr: Staphylococcus aureus infections:
Epidemiology, pathophysiology, clinical manifestations, and
management. Clin Microbiol Rev. 28:603–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Craven RR, Gao X, Allen IC, Gris D, Bubeck
Wardenburg J, McElvania-Tekippe E, Ting JP and Duncan JA:
Staphylococcus aureus alpha-hemolysin activates the NLRP3
inflammasome in human and mouse monocytic cells. PLoS One.
4:e74462009. View Article : Google Scholar
|
|
76
|
Kebaier C, Chamberland RR, Allen IC, Gao
X, Broglie PM, Hall JD, Jania C, Doerschuk CM, Tilley SL and Duncan
JA: Staphylococcus aureus α-hemolysin mediates virulence in a
murine model of severe pneumonia through activation of the NLRP3
inflammasome. J Infect Dis. 205:807–817. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bewley MA, Naughton M, Preston J, Mitchell
A, Holmes A, Marriott HM, Read RC, Mitchell TJ, Whyte MK and
Dockrell DH: Pneumolysin activates macrophage lysosomal membrane
permeabilization and executes apoptosis by distinct mechanisms
without membrane pore formation. mBio. 5:e01710–14. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Witzenrath M, Pache F, Lorenz D, Koppe U,
Gutbier B, Tabeling C, Reppe K, Meixenberger K, Dorhoi A, Ma J, et
al: The NLRP3 inflammasome is differentially activated by
pneumolysin variants and contributes to host defense in
pneumococcal pneumonia. J Immunol. 187:434–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
McNeela EA, Burke A, Neill DR, Baxter C,
Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM,
Mori A, et al: Pneumolysin activates the NLRP3 inflammasome and
promotes proinflammatory cytokines independently of TLR4. PLoS
Pathog. 6:e10011912010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
van Lieshout MH, Scicluna BP, Florquin S
and van der Poll T: NLRP3 and ASC differentially affect the lung
transcriptome during pneumococcal pneumonia. Am J Respir Cell Mol
Biol. 50:699–712. 2014. View Article : Google Scholar
|
|
81
|
Gravina AG, Zagari RM, De Musis C, Romano
L, Loguercio C and Romano M: Helicobacter pylori and extragastric
diseases: A review. World J Gastroenterol. 24:3204–3221. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Venerito M, Vasapolli R, Rokkas T,
Delchier JC and Malfertheiner P: Helicobacter pylori, gastric
cancer and other gastrointestinal malignancies. Helicobacter.
22(Suppl 1)John Wiley and Sons; 2017, View Article : Google Scholar
|
|
83
|
Pachathundikandi SK, Blaser N, Bruns H and
Backert S: Helicobacter pylori avoids the critical activation of
NLRP3 inflammasome-mediated production of oncogenic mature IL-1β in
human immune cells. Cancers (Basel). 12:8032020. View Article : Google Scholar
|
|
84
|
Li X, Liu S, Luo J, Liu A, Tang S, Liu S,
Yu M and Zhang Y: Helicobacter pylori induces IL-1β and IL-18
production in human monocytic cell line through activation of NLRP3
inflammasome via ROS signaling pathway. Pathog Dis. 73:ftu0242015.
View Article : Google Scholar
|
|
85
|
Shigematsu Y, Niwa T, Rehnberg E, Toyoda
T, Yoshida S, Mori A, Wakabayashi M, Iwakura Y, Ichinose M, Kim YJ
and Ushijima T: Interleukin-1β induced by Helicobacter pylori
infection enhances mouse gastric carcinogenesis. Cancer Lett.
340:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Serizawa T, Hirata Y, Hayakawa Y, Suzuki
N, Sakitani K, Hikiba Y, Ihara S, Kinoshita H, Nakagawa H, Tateishi
K and Koike K: Gastric metaplasia induced by helicobacter pylori is
associated with enhanced SOX9 expression via interleukin-1
signaling. Infect Immun. 84:562–572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kameoka S, Kameyama T, Hayashi T, Sato S,
Ohnishi N, Hayashi T, Murata-Kamiya N, Higashi H, Hatakeyama M and
Takaoka A: Helicobacter pylori induces IL-1β protein through the
inflammasome activation in differentiated macrophagic cells. Biomed
Res. 37:21–27. 2016. View Article : Google Scholar
|
|
88
|
Yu Q, Shi H, Ding Z, Wang Z, Yao H and Lin
R: The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome
activation in Helicobacter pylori-associated gastritis by
regulating ROS and autophagy. Cell Commun Signal. 21:12023.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Davari F, Shokri-Shirvani J, Sepidarkish M
and Nouri HR: Elevated expression of the AIM2 gene in response to
Helicobacter pylori along with the decrease of NLRC4 inflammasome
is associated with peptic ulcer development. APMIS. 131:339–350.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Asrani SK, Devarbhavi H, Eaton J and
Kamath PS: Burden of liver diseases in the world. J Hepatol.
70:151–171. 2019. View Article : Google Scholar
|
|
91
|
Sharma A and Nagalli S: Chronic Liver
Disease. StatPearls [Internet] Treasure Island, FL: 2023
|
|
92
|
Wree A, McGeough MD, Peña CA, Schlattjan
M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM and
Feldstein AE: NLRP3 inflammasome activation is required for
fibrosis development in NAFLD. J Mol Med (Berl). 92:1069–1082.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Arab JP, Arrese M and Trauner M: Recent
insights into the pathogenesis of nonalcoholic fatty liver disease.
Annu Rev Pathol. 13:321–350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ and
Jo EK: Upregulated NLRP3 inflammasome activation in patients with
type 2 diabetes. Diabetes. 62:194–204. 2013. View Article : Google Scholar
|
|
95
|
Vandanmagsar B, Youm YH, Ravussin A,
Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM and Dixit
VD: The NLRP3 inflammasome instigates obesity-induced inflammation
and insulin resistance. Nat Med. 17:179–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Csak T, Ganz M, Pespisa J, Kodys K,
Dolganiuc A and Szabo G: Fatty acid and endotoxin activate
inflammasomes in mouse hepatocytes that release danger signals to
stimulate immune cells. Hepatology. 54:133–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Mellinger JL: Epidemiology of alcohol use
and alcoholic liver disease. Clin Liver Dis (Hoboken). 13:136–139.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ohashi K, Pimienta M and Seki E: Alcoholic
liver disease: A current molecular and clinical perspective. Liver
Res. 2:161–172. 2018. View Article : Google Scholar
|
|
99
|
Voican CS, Njiké-Nakseu M, Boujedidi H,
Barri-Ova N, Bouchet-Delbos L, Agostini H, Maitre S, Prévot S,
Cassard-Doulcier AM, Naveau S and Perlemuter G: Alcohol withdrawal
alleviates adipose tissue inflammation in patients with alcoholic
liver disease. Liver Int. 35:967–978. 2015. View Article : Google Scholar
|
|
100
|
Petrasek J, Bala S, Csak T, Lippai D,
Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA and Szabo G:
IL-1 receptor antagonist ameliorates inflammasome-dependent
alcoholic steatohepatitis in mice. J Clin Invest. 122:3476–3489.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Dixon LJ, Berk M, Thapaliya S, Papouchado
BG and Feldstein AE: Caspase-1-mediated regulation of fibrogenesis
in diet-induced steatohepatitis. Lab Invest. 92:713–723. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Boaru SG, Borkham-Kamphorst E, Tihaa L,
Haas U and Weiskirchen R: Expression analysis of inflammasomes in
experimental models of inflammatory and fibrotic liver disease. J
Inflamm (Lond). 9:492012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Alyaseer AAA, de Lima MHS and Braga TT:
The role of NLRP3 inflammasome activation in the epithelial to
mesenchymal transition process during the fibrosis. Front Immunol.
11:8832020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lozano-Ruiz B, Bachiller V,
García-Martínez I, Zapater P, Gómez-Hurtado I, Moratalla A, Giménez
P, Bellot P, Francés R, Such J and González-Navajas JM: Absent in
melanoma 2 triggers a heightened inflammasome response in ascitic
fluid macrophages of patients with cirrhosis. J Hepatol. 62:64–71.
2015. View Article : Google Scholar
|
|
106
|
Liu X, Zhou W, Zhang X, Lu P, Du Q, Tao L,
Ding Y, Wang Y and Hu R: Dimethyl fumarate ameliorates dextran
sulfate sodium-induced murine experimental colitis by activating
Nrf2 and suppressing NLRP3 inflammasome activation. Biochem
Pharmacol. 112:37–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sivakumar PV, Westrich GM, Kanaly S, Garka
K, Born TL, Derry JM and Viney JL: Interleukin 18 is a primary
mediator of the inflammation associated with dextran sulphate
sodium induced colitis: Blocking interleukin 18 attenuates
intestinal damage. Gut. 50:812–820. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Siegmund B, Fantuzzi G, Rieder F,
Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S
and Eigler A: Neutralization of interleukin-18 reduces severity in
murine colitis and intestinal IFN-gamma and TNF-alpha production.
Am J Physiol Regul Integr Comp Physiol. 281:R1264–R1273. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Siegmund B: Interleukin-1beta converting
enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol.
64:1–8. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhao S, Gong Z, Zhou J, Tian C, Gao Y, Xu
C, Chen Y, Cai W and Wu J: Deoxycholic acid triggers NLRP3
inflammasome activation and aggravates DSS-induced colitis in mice.
Front Immunol. 7:5362016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zherebiatiev A and Kamyshnyi A: Expression
levels of proinflammatory cytokines and NLRP3 inflammasome in an
experimental model of oxazolone-induced colitis. Iran J Allergy
Asthma Immunol. 15:39–45. 2016.PubMed/NCBI
|
|
112
|
Bauer C, Duewell P, Lehr HA, Endres S and
Schnurr M: Protective and aggravating effects of Nlrp3 inflammasome
activation in IBD models: Influence of genetic and environmental
factors. Dig Dis. 30(Suppl 1): S82–S90. 2012. View Article : Google Scholar
|
|
113
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zaki MH, Boyd KL, Vogel P, Kastan MB,
Lamkanfi M and Kanneganti TD: The NLRP3 inflammasome protects
against loss of epithelial integrity and mortality during
experimental colitis. Immunity. 32:379–391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dupaul-Chicoine J, Yeretssian G, Doiron K,
Bergstrom KS, McIntire CR, LeBlanc PM, Meunier C, Turbide C, Gros
P, Beauchemin N, et al: Control of intestinal homeostasis, colitis,
and colitis-associated colorectal cancer by the inflammatory
caspases. Immunity. 32:367–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Radtke F and Clevers H: Self-renewal and
cancer of the gut: two sides of a coin. Science. 307:1904–1909.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Itzkowitz SH and Yio X: Inflammation and
cancer IV. Colorectal cancer in inflammatory bowel disease: The
role of inflammation. Am J Physiol Gastrointest Liver Physiol.
287:G7–G17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Du Q, Wang Q, Fan H, Wang J, Liu X, Wang
H, Wang Y and Hu R: Dietary cholesterol promotes AOM-induced
colorectal cancer through activating the NLRP3 inflammasome.
Biochem Pharmacol. 105:42–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Micallef MJ, Tanimoto T, Kohno K, Ikeda M
and Kurimoto M: Interleukin 18 induces the sequential activation of
natural killer cells and cytotoxic T lymphocytes to protect
syngeneic mice from transplantation with Meth A sarcoma. Cancer
Res. 57:4557–4563. 1997.PubMed/NCBI
|
|
120
|
Micallef MJ, Yoshida K, Kawai S, Hanaya T,
Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M and
Kurimoto M: In vivo antitumor effects of murine
interferon-gamma-inducing factor/interleukin-18 in mice bearing
syngeneic Meth A sarcoma malignant ascites. Cancer Immunol
Immunother. 43:361–367. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Osaki T, Péron JM, Cai Q, Okamura H,
Robbins PD, Kurimoto M, Lotze MT and Tahara H: IFN-gamma-inducing
factor/IL-18 administration mediates IFN-gamma- and
IL-12-independent antitumor effects. J Immunol. 160:1742–1749.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Coughlin CM, Salhany KE, Wysocka M, Aruga
E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G and Lee WM:
Interleukin-12 and interleukin-18 synergistically induce murine
tumor regression which involves inhibition of angiogenesis. J Clin
Invest. 101:1441–1452. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hegardt P, Widegren B, Li L, Sjögren B,
Kjellman C, Sur I and Sjögren HO: Nitric oxide synthase inhibitor
and IL-18 enhance the anti-tumor immune response of rats carrying
an intrahepatic colon carcinoma. Cancer Immunol Immunother.
50:491–501. 2001. View Article : Google Scholar
|
|
124
|
Zaki MH, Vogel P, Body-Malapel M, Lamkanfi
M and Kanneganti TD: IL-18 production downstream of the Nlrp3
inflammasome confers protection against colorectal tumor formation.
J Immunol. 185:4912–4920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Reuter BK and Pizarro TT: Commentary: the
role of the IL-18 system and other members of the IL-1R/TLR
superfamily in innate mucosal immunity and the pathogenesis of
inflammatory bowel disease: Friend or foe? Eur J Immunol.
34:2347–2355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Swaroop VS, Chari ST and Clain JE: Severe
acute pancreatitis. JAMA. 291:2865–2868. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yang ZW, Meng XX and Xu P: Central role of
neutrophil in the pathogenesis of severe acute pancreatitis. J Cell
Mol Med. 19:2513–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Janiak A, Leśniowski B, Jasińska A,
Pietruczuk M and Małecka-Panas E: Interleukin 18 as an early marker
or prognostic factor in acute pancreatitis. Prz Gastroenterol.
10:203–207. 2015.
|
|
129
|
Fu Q, Zhai Z, Wang Y, Xu L, Jia P, Xia P,
Liu C, Zhang X, Qin T and Zhang H: NLRP3 deficiency alleviates
severe acute pancreatitis and pancreatitis-associated lung injury
in a mouse model. Biomed Res Int. 2018:12949512018. View Article : Google Scholar
|
|
130
|
Hoque R, Farooq A, Ghani A, Gorelick F and
Mehal WZ: Lactate reduces liver and pancreatic injury in Toll-like
receptor- and inflammasome-mediated inflammation via GPR81-mediated
suppression of innate immunity. Gastroenterology. 146:1763–1774.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Wu BU, Hwang JQ, Gardner TH, Repas K,
Delee R, Yu S, Smith B, Banks PA and Conwell DL: Lactated Ringer's
solution reduces systemic inflammation compared with saline in
patients with acute pancreatitis. Clin Gastroenterol Hepatol.
9:710–717.e1. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ren JD, Ma J, Hou J, Xiao WJ, Jin WH, Wu J
and Fan KH: Hydrogen-rich saline inhibits NLRP3 inflammasome
activation and attenuates experimental acute pancreatitis in mice.
Mediators Inflamm. 2014:9308942014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Smolen JS, Aletaha D, Barton A, Burmester
GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH,
Strand V and Yamamoto K: Rheumatoid arthritis. Nat Rev Dis Primers.
4:180012018. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Kolly L, Busso N, Palmer G, Talabot-Ayer
D, Chobaz V and So A: Expression and function of the NALP3
inflammasome in rheumatoid synovium. Immunology. 129:178–185. 2010.
View Article : Google Scholar :
|
|
135
|
Rosengren S, Hoffman HM, Bugbee W and
Boyle DL: Expression and regulation of cryopyrin and related
proteins in rheumatoid arthritis synovium. Ann Rheum Dis.
64:708–714. 2005. View Article : Google Scholar
|
|
136
|
Choulaki C, Papadaki G, Repa A, Kampouraki
E, Kambas K, Ritis K, Bertsias G, Boumpas DT and Sidiropoulos P:
Enhanced activity of NLRP3 inflammasome in peripheral blood cells
of patients with active rheumatoid arthritis. Arthritis Res Ther.
17:2572015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhang Y, Zheng Y and Li H: NLRP3
Inflammasome plays an important role in the pathogenesis of
collagen-induced arthritis. Mediators Inflamm. 2016:96562702016.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Guo C, Fu R, Wang S, Huang Y, Li X, Zhou
M, Zhao J and Yang N: NLRP3 inflammasome activation contributes to
the pathogenesis of rheumatoid arthritis. Clin Exp Immunol.
194:231–243. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Matmati M, Jacques P, Maelfait J,
Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Mc Guire C,
Vereecke L, et al: A20 (TNFAIP3) deficiency in myeloid cells
triggers erosive polyarthritis resembling rheumatoid arthritis. Nat
Genet. 43:908–912. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
140
|
Vande Walle L, Van Opdenbosch N, Jacques
P, Fossoul A, Verheugen E, Vogel P, Beyaert R, Elewaut D,
Kanneganti TD, van Loo G and Lamkanfi M: Negative regulation of the
NLRP3 inflammasome by A20 protects against arthritis. Nature.
512:69–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Li XF, Shen WW, Sun YY, Li WX, Sun ZH, Liu
YH, Zhang L, Huang C, Meng XM and Li J: MicroRNA-20a negatively
regulates expression of NLRP3 inflammasome by targeting TXNIP in
adjuvant-induced arthritis fibroblast-like synoviocytes. Joint Bone
Spine. 83:695–700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Huang Y, Lu D, Ma W, Liu J, Ning Q, Tang F
and Li L: miR-223 in exosomes from bone marrow mesenchymal stem
cells ameliorates rheumatoid arthritis via downregulation of NLRP3
expression in macrophages. Mol Immunol. 143:68–76. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li Y, Zheng JY, Liu JQ, Yang J, Liu Y,
Wang C, Ma XN, Liu BL, Xin GZ and Liu LF: Succinate/NLRP3
inflammasome induces synovial fibroblast activation: Therapeutical
effects of clematichinenoside AR on arthritis. Front Immunol.
7:5322016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Han X, Lin D, Huang W, Li D, Li N and Xie
X: Mechanism of NLRP3 inflammasome intervention for synovitis in
knee osteoarthritis: A review of TCM intervention. Front Genet.
14:11591672023. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Derfus BA, Kurian JB, Butler JJ, Daft LJ,
Carrera GF, Ryan LM and Rosenthal AK: The high prevalence of
pathologic calcium crystals in pre-operative knees. J Rheumatol.
29:570–574. 2002.PubMed/NCBI
|
|
146
|
Pazár B, Ea HK, Narayan S, Kolly L,
Bagnoud N, Chobaz V, Roger T, Lioté F, So A and Busso N: Basic
calcium phosphate crystals induce monocyte/macrophage IL-1β
secretion through the NLRP3 inflammasome in vitro. J Immunol.
186:2495–2502. 2011. View Article : Google Scholar
|
|
147
|
An S, Hu H, Li Y and Hu Y: Pyroptosis
plays a role in osteoarthritis. Aging Dis. 11:1146–1157. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Shao M, Lv D, Zhou K, Sun H and Wang Z:
Senkyunolide A inhibits the progression of osteoarthritis by
inhibiting the NLRP3 signalling pathway. Pharm Biol. 60:535–542.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Lordén G, Sanjuán-García I, de Pablo N,
Meana C, Alvarez-Miguel I, Pérez-García MT, Pelegrín P, Balsinde J
and Balboa MA: Lipin-2 regulates NLRP3 inflammasome by affecting
P2X7 receptor activation. J Exp Med. 214:511–528. 2017. View Article : Google Scholar :
|
|
150
|
Compston JE, McClung MR and Leslie WD:
Osteoporosis. Lancet. 393:364–376. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Alippe Y, Wang C, Ricci B, Xiao J, Qu C,
Zou W, Novack DV, Abu-Amer Y, Civitelli R and Mbalaviele G: Bone
matrix components activate the NLRP3 inflammasome and promote
osteoclast differentiation. Sci Rep. 7:66302017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Detzen L, Cheat B, Besbes A, Hassan B,
Marchi V, Baroukh B, Lesieur J, Sadoine J, Torrens C, Rochefort G,
et al: NLRP3 is involved in long bone edification and the
maturation of osteogenic cells. J Cell Physiol. 236:4455–4469.
2021. View Article : Google Scholar
|
|
153
|
Jiang N, An J, Yang K, Liu J, Guan C, Ma C
and Tang X: NLRP3 Inflammasome: A new target for prevention and
control of osteoporosis? Front Endocrinol (Lausanne).
12:7525462021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Rocha FRG, Delitto AE, de Souza JAC,
González-Maldonado LA, Wallet SM and Rossa Junior C: Relevance of
caspase-1 and Nlrp3 inflammasome on inflammatory bone resorption in
a murine model of periodontitis. Sci Rep. 10:78232020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wang C, Xiao J, Nowak K, Gunasekera K,
Alippe Y, Speckman S, Yang T, Kress D, Abu-Amer Y, Hottiger MO and
Mbalaviele G: PARP1 hinders histone H2B occupancy at the NFATc1
promoter to restrain osteoclast differentiation. J Bone Miner Res.
35:776–788. 2020. View Article : Google Scholar
|
|
156
|
Guaraná WL, Lima CAD, Barbosa AD, Crovella
S and Sandrin-Garcia P: Can polymorphisms in NLRP3 inflammasome
complex be associated with postmenopausal osteoporosis severity?
Genes (Basel). 13:22712022. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Xu L, Zhang L, Wang Z, Li C, Li S, Li L,
Fan Q and Zheng L: Melatonin suppresses estrogen deficiency-induced
osteoporosis and promotes osteoblastogenesis by inactivating the
NLRP3 inflammasome. Calcif Tissue Int. 103:400–410. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Dehlin M, Jacobsson L and Roddy E: Global
epidemiology of gout: Prevalence, incidence, treatment patterns and
risk factors. Nat Rev Rheumatol. 16:380–390. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Mangan MSJ, Olhava EJ, Roush WR, Seidel
HM, Glick GD and Latz E: Targeting the NLRP3 inflammasome in
inflammatory diseases. Nat Rev Drug Discov. 17:6882018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhao Q, Xia N, Xu J, Wang Y, Feng L, Su D
and Cheng Z: Pro-Inflammatory of PRDM1/SIRT2/NLRP3 axis in
monosodium urate-induced acute gouty arthritis. J Innate Immun.
15:614–628. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Renaudin F, Orliaguet L, Castelli F,
Fenaille F, Prignon A, Alzaid F, Combes C, Delvaux A, Adimy Y,
Cohen-Solal M, et al: Gout and pseudo-gout-related crystals promote
GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β
activation on macrophages. Ann Rheum Dis. 79:1506–1514. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Lee HE, Yang G, Park YB, Kang HC, Cho YY,
Lee HS and Lee JY: Epigallocatechin-3-gallate prevents acute gout
by suppressing NLRP3 inflammasome activation and mitochondrial DNA
synthesis. Molecules. 24:21382019. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Li X, Liu Y, Luo C and Tao J: Z1456467176
alleviates gouty arthritis by allosterically modulating P2X7R to
inhibit NLRP3 inflammasome activation. Front Pharmacol.
13:9799392022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Xin J, Wang Y, Zheng Z, Wang S, Na S and
Zhang S: Treatment of intervertebral disc degeneration. Orthop
Surg. 14:1271–1280. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Chen F, Jiang G, Liu H, Li Z, Pei Y, Wang
H, Pan H, Cui H, Long J, Wang J and Zheng Z: Melatonin alleviates
intervertebral disc degeneration by disrupting the
IL-1β/NF-κB-NLRP3 inflammasome positive feedback loop. Bone Res.
8:102020. View Article : Google Scholar
|
|
166
|
Chen S, Wu X, Lai Y, Chen D, Bai X, Liu S,
Wu Y, Chen M, Lai Y, Cao H, et al: Kindlin-2 inhibits Nlrp3
inflammasome activation in nucleus pulposus to maintain homeostasis
of the intervertebral disc. Bone Res. 10:52022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Zhao K, An R, Xiang Q, Li G, Wang K, Song
Y, Liao Z, Li S, Hua W, Feng X, et al: Acid-sensing ion channels
regulate nucleus pulposus cell inflammation and pyroptosis via the
NLRP3 inflammasome in intervertebral disc degeneration. Cell
Prolif. 54:e129412021. View Article : Google Scholar
|
|
168
|
Wojtasińska A, Frąk W, Lisińska W, Sapeda
N, Młynarska E, Rysz J and Franczyk B: Novel insights into the
molecular mechanisms of atherosclerosis. Int J Mol Sci.
24:134342023. View Article : Google Scholar
|
|
169
|
Duewell P, Kono H, Rayner KJ, Sirois CM,
Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr
M, et al: NLRP3 inflammasomes are required for atherogenesis and
activated by cholesterol crystals. Nature. 464:1357–1361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Paramel Varghese G, Folkersen L,
Strawbridge RJ, Halvorsen B, Yndestad A, Ranheim T, Krohg-Sørensen
K, Skjelland M, Espevik T, Aukrust P, et al: NLRP3 inflammasome
expression and activation in human atherosclerosis. J Am Heart
Assoc. 5:e0030312016. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Usui F, Shirasuna K, Kimura H, Tatsumi K,
Kawashima A, Karasawa T, Hida S, Sagara J, Taniguchi S and
Takahashi M: Critical role of caspase-1 in vascular inflammation
and development of atherosclerosis in Western diet-fed
apolipoprotein E-deficient mice. Biochem Biophys Res Commun.
425:162–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Zheng F, Xing S, Gong Z, Mu W and Xing Q:
Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques
in apolipoprotein E-deficient mice. Mediators Inflamm.
2014:5072082014. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Satoh M, Tabuchi T, Itoh T and Nakamura M:
NLRP3 inflammasome activation in coronary artery disease: Results
from prospective and randomized study of treatment with
atorvastatin or rosuvastatin. Clin Sci (Lond). 126:233–241. 2014.
View Article : Google Scholar
|
|
174
|
Butts B, Gary RA, Dunbar SB and Butler J:
The importance of NLRP3 inflammasome in heart failure. J Card Fail.
21:586–593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Bracey NA, Beck PL, Muruve DA, Hirota SA,
Guo J, Jabagi H, Wright JR Jr, Macdonald JA, Lees-Miller JP, Roach
D, et al: The Nlrp3 inflammasome promotes myocardial dysfunction in
structural cardiomyopathy through interleukin-1β. Exp Physiol.
98:462–472. 2013. View Article : Google Scholar
|
|
176
|
Mezzaroma E, Toldo S, Farkas D, Seropian
IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF and
Abbate A: The inflammasome promotes adverse cardiac remodeling
following acute myocardial infarction in the mouse. Proc Natl Acad
Sci USA. 108:19725–19730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Van Tassell BW, Seropian IM, Toldo S,
Mezzaroma E and Abbate A: Interleukin-1β induces a reversible
cardiomyopathy in the mouse. Inflamm Res. 62:637–640. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Toldo S, Mezzaroma E, O'Brien L, Marchetti
C, Seropian IM, Voelkel NF, Van Tassell BW, Dinarello CA and Abbate
A: Interleukin-18 mediates interleukin-1-induced cardiac
dysfunction. Am J Physiol Heart Circ Physiol. 306:H1025–H1031.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Abbate A, Kontos MC, Grizzard JD,
Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA,
Roberts CS, Varma A, et al: Interleukin-1 blockade with anakinra to
prevent adverse cardiac remodeling after acute myocardial
infarction (Virginia Commonwealth University Anakinra Remodeling
Trial (VCU-ART) Pilot study). Am J Cardiol. 105:1371–1377.e1. 2010.
View Article : Google Scholar
|
|
180
|
Abbate A, Van Tassell BW, Biondi-Zoccai G,
Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior
RD, Mueller GH, et al: Effects of interleukin-1 blockade with
anakinra on adverse cardiac remodeling and heart failure after
acute myocardial infarction (from the Virginia Commonwealth
University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study).
Am J Cardiol. 111:1394–1400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Kawaguchi M, Takahashi M, Hata T, Kashima
Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J,
et al: Inflammasome activation of cardiac fibroblasts is essential
for myocardial ischemia/reperfusion injury. Circulation.
123:594–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Sandanger Ø, Ranheim T, Vinge LE, Bliksøen
M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G,
Christensen G, et al: The NLRP3 inflammasome is up-regulated in
cardiac fibroblasts and mediates myocardial ischaemia-reperfusion
injury. Cardiovasc Res. 99:164–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao
C, Xin C, Zhu D, Li Y, Yan W, et al: TXNIP mediates NLRP3
inflammasome activation in cardiac microvascular endothelial cells
as a novel mechanism in myocardial ischemia/reperfusion injury.
Basic Res Cardiol. 109:4152014. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Capizzi A, Woo J and Verduzco-Gutierrez M:
Traumatic brain injury: An overview of epidemiology,
pathophysiology, and medical management. Med Clin North Am.
104:213–238. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Liu W, Chen Y, Meng J, Wu M, Bi F, Chang
C, Li H and Zhang L: Ablation of caspase-1 protects against
TBI-induced pyroptosis in vitro and in vivo. J Neuroinflammation.
15:482018. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Xu X, Yin D, Ren H, Gao W, Li F, Sun D, Wu
Y, Zhou S, Lyu L, Yang M, et al: Selective NLRP3 inflammasome
inhibitor reduces neuroinflammation and improves long-term
neurological outcomes in a murine model of traumatic brain injury.
Neurobiol Dis. 117:15–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Wallisch JS, Simon DW, Bayır H, Bell MJ,
Kochanek PM and Clark RSB: Cerebrospinal fluid NLRP3 is increased
after severe traumatic brain injury in infants and children.
Neurocrit Care. 27:44–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Geng F, Ma Y, Xing T, Zhuang X, Zhu J and
Yao L: Effects of hyperbaric oxygen therapy on inflammasome
signaling after traumatic brain injury. Neuroimmunomodulation.
23:122–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Marino BLB, de Souza LR, Sousa KPA,
Ferreira JV, Padilha EC, da Silva CHTP, Taft CA and Hage-Melim LIS:
Parkinson's disease: A review from pathophysiology to treatment.
Mini Rev Med Chem. 20:754–767. 2020. View Article : Google Scholar
|
|
190
|
Marogianni C, Sokratous M, Dardiotis E,
Hadjigeorgiou GM, Bogdanos D and Xiromerisiou G: Neurodegeneration
and Inflammation-an interesting interplay in Parkinson's disease.
Int J Mol Sci. 21:84212020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Mao Z, Liu C, Ji S, Yang Q, Ye H, Han H
and Xue Z: The NLRP3 inflammasome is involved in the pathogenesis
of Parkinson's disease in rats. Neurochem Res. 42:1104–1115. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Qiao C, Zhang Q, Jiang Q, Zhang T, Chen M,
Fan Y, Ding J, Lu M and Hu G: Inhibition of the hepatic Nlrp3
protects dopaminergic neurons via attenuating systemic inflammation
in a MPTP/p mouse model of Parkinson's disease. J
Neuroinflammation. 15:1932018. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Villain N and Dubois B: Alzheimer's
disease including focal presentations. Semin Neurol. 39:213–226.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Cummings JL, Tong G and Ballard C:
Treatment combinations for Alzheimer's disease: Current and future
pharmacotherapy options. J Alzheimers Dis. 67:779–794. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Abbott A: Is 'friendly fire' in the brain
provoking Alzheimer's disease? Nature. 556:426–428. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Zhang Y, Dong Z and Song W: NLRP3
inflammasome as a novel therapeutic target for Alzheimer's disease.
Signal Transduct Target Ther. 5:372020. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Ising C, Venegas C, Zhang S, Scheiblich H,
Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM,
Tejera D, et al: NLRP3 inflammasome activation drives tau
pathology. Nature. 575:669–673. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Srinivasan S, Kancheva D, De Ren S, Saito
T, Jans M, Boone F, Vandendriessche C, Paesmans I, Maurin H,
Vandenbroucke RE, et al: Inflammasome signaling is dispensable for
ß-amyloid-induced neuropathology in preclinical models of
Alzheimer's disease. Front Immunol. 15:13234092024. View Article : Google Scholar
|
|
199
|
Dobson R and Giovannoni G: Multiple
sclerosis-a review. Eur J Neurol. 26:27–40. 2019. View Article : Google Scholar
|
|
200
|
Inoue M, Williams KL, Gunn MD and
Shinohara ML: NLRP3 inflammasome induces chemotactic immune cell
migration to the CNS in experimental autoimmune encephalomyelitis.
Proc Natl Acad Sci USA. 109:10480–10485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Zhao Y, Zhang X, Chen X and Wei Y:
Neuronal injuries in cerebral infarction and ischemic stroke: From
mechanisms to treatment (Review). Int J Mol Med. 49:152022.
View Article : Google Scholar :
|
|
202
|
Zhao J, Piao X, Wu Y, Liang S, Han F,
Liang Q, Shao S and Zhao D: Cepharanthine attenuates cerebral
ischemia/reperfusion injury by reducing NLRP3 inflammasome-induced
inflammation and oxidative stress via inhibiting 12/15-LOX
signaling. Biomed Pharmacother. 127:1101512020. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Wang H, Zhong D, Chen H, Jin J, Liu Q and
Li G: NLRP3 inflammasome activates interleukin-23/interleukin-17
axis during ischaemia-reperfusion injury in cerebral ischaemia in
mice. Life Sci. 227:101–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Silveira LS, Antunes Bde M, Minari AL, Dos
Santos RV, Neto JC and Lira FS: Macrophage polarization:
Implications on metabolic diseases and the role of exercise. Crit
Rev Eukaryot Gene Expr. 26:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Luo L, Liu M, Fan Y, Zhang J, Liu L, Li Y,
Zhang Q, Xie H, Jiang C, Wu J, et al: Intermittent theta-burst
stimulation improves motor function by inhibiting neuronal
pyroptosis and regulating microglial polarization via
TLR4/NFκB/NLRP3 signaling pathway in cerebral ischemic mice. J
Neuroinflammation. 19:1412022. View Article : Google Scholar
|
|
206
|
Ye X, Shen T, Hu J, Zhang L, Zhang Y, Bao
L, Cui C, Jin G, Zan K, Zhang Z, et al: Purinergic 2X7
receptor/NLRP3 pathway triggers neuronal apoptosis after ischemic
stroke in the mouse. Exp Neurol. 292:46–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Seok JK, Kang HC, Cho YY, Lee HS and Lee
JY: Therapeutic regulation of the NLRP3 inflammasome in chronic
inflammatory diseases. Arch Pharm Res. 44:16–35. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y,
Shen Y, Li J, Tan R, Xu Q and Sun Y: A novel benzo(d)imidazole
derivate prevents the development of dextran sulfate sodium-induced
murine experimental colitis via inhibition of NLRP3 inflammasome.
Biochem Pharmacol. 85:1504–1512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Youm YH, Nguyen KY, Grant RW, Goldberg EL,
Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti
TD, et al: The ketone metabolite β-hydroxybutyrate blocks NLRP3
inflammasome-mediated inflammatory disease. Nat Med. 21:263–269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Yan CY, Ouyang SH, Wang X, Wu YP, Sun WY,
Duan WJ, Liang L, Luo X, Kurihara H, Li YF and He RR: Celastrol
ameliorates propionibacterium acnes/LPS-induced liver damage and
MSU-induced gouty arthritis via inhibiting K63 deubiquitination of
NLRP3. Phytomedicine. 80:1533982021. View Article : Google Scholar
|
|
211
|
Li M, Liu H, Shao H, Zhang P, Gao M, Huang
L, Shang P, Zhang Q, Wang W and Feng F: Glyburide attenuates B(a)p
and LPS-induced inflammation-related lung tumorigenesis in mice.
Environ Toxicol. 36:1713–1722. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Yang G, Lee HE, Moon SJ, Ko KM, Koh JH,
Seok JK, Min JK, Heo TH, Kang HC, Cho YY, et al: Direct binding to
NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven
inflammation and gouty arthritis. Arthritis Rheumatol.
72:1192–1202. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Jiang H, He H, Chen Y, Huang W, Cheng J,
Ye J, Wang A, Tao J, Wang C, Liu Q, et al: Identification of a
selective and direct NLRP3 inhibitor to treat inflammatory
disorders. J Exp Med. 214:3219–3238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
He Y, Varadarajan S, Muñoz-Planillo R,
Burberry A, Nakamura Y and Núñez G:
3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome
activation by blocking assembly of the inflammasome. J Biol Chem.
289:1142–1150. 2014. View Article : Google Scholar
|
|
215
|
Juliana C, Fernandes-Alnemri T, Wu J,
Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP and
Alnemri ES: Anti-inflammatory compounds parthenolide and Bay
11-7082 are direct inhibitors of the inflammasome. J Biol Chem.
285:9792–9802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Kerr ID, Lee JH, Farady CJ, Marion R,
Rickert M, Sajid M, Pandey KC, Caffrey CR, Legac J, Hansell E, et
al: Vinyl sulfones as antiparasitic agents and a structural basis
for drug design. J Biol Chem. 284:25697–25703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Lee HE, Yang G, Kim ND, Jeong S, Jung Y,
Choi JY, Park HH and Lee JY: Targeting ASC in NLRP3 inflammasome by
caffeic acid phenethyl ester: A novel strategy to treat acute gout.
Sci Rep. 6:386222016. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Linton SD: Caspase inhibitors: a
pharmaceutical industry perspective. Curr Top Med Chem.
5:1697–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Dinarello CA, Simon A and van der Meer JW:
Treating inflammation by blocking interleukin-1 in a broad spectrum
of diseases. Nat Rev Drug Discov. 11:633–652. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: Antiinflammatory therapy with canakinumab for
atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Neudecker V, Haneklaus M, Jensen O,
Khailova L, Masterson JC, Tye H, Tye H, Biette K, Jedlicka P,
Brodsky KS, et al: Myeloid-derived miR-223 regulates intestinal
inflammation via repression of the NLRP3 inflammasome. J Exp Med.
214:1737–1752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Feng Z, Qi S, Zhang Y, Qi Z, Yan L, Zhou
J, He F, Li Q, Yang Y, Chen Q, et al: Ly6G+ neutrophil-derived
miR-223 inhibits the NLRP3 inflammasome in mitochondrial
DAMP-induced acute lung injury. Cell Death Dis. 8:e31702017.
View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Bandyopadhyay S, Lane T, Venugopal R,
Parthasarathy PT, Cho Y, Galam L, Lockey R and Kolliputi N:
MicroRNA-133a-1 regulates inflammasome activation through
uncoupling protein-2. Biochem Biophys Res Commun. 439:407–412.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Li S, Liang X, Ma L, Shen L, Li T, Zheng
L, Sun A, Shang W, Chen C, Zhao W and Jia J: MiR-22 sustains NLRP3
expression and attenuates H. pylori-induced gastric carcinogenesis.
Oncogene. 37:884–896. 2018. View Article : Google Scholar
|
|
226
|
Li D, Yang H, Ma J, Luo S, Chen S and Gu
Q: MicroRNA-30e regulates neuroinflammation in MPTP model of
Parkinson's disease by targeting Nlrp3. Hum Cell. 31:106–115. 2018.
View Article : Google Scholar
|
|
227
|
Zhou Y, Lu M, Du RH, Qiao C, Jiang CY,
Zhang KZ, Ding JH and Hu G: MicroRNA-7 targets Nod-like receptor
protein 3 inflammasome to modulate neuroinflammation in the
pathogenesis of Parkinson's disease. Mol Neurodegener. 11:282016.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Boxberger N, Hecker M and Zettl UK:
Dysregulation of inflammasome priming and activation by MicroRNAs
in human immune-mediated diseases. J Immunol. 202:2177–2187. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Tezcan G, Martynova EV, Gilazieva ZE,
McIntyre A, Rizvanov AA and Khaiboullina SF: MicroRNA
post-transcriptional regulation of the NLRP3 inflammasome in
immunopathologies. Front Pharmacol. 10:4512019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Zhou T, Xiang DK, Li SN, Yang LH, Gao LF
and Feng C: MicroRNA-495 ameliorates cardiac microvascular
endothelial cell injury and inflammatory reaction by suppressing
the NLRP3 inflammasome signaling pathway. Cell Physiol Biochem.
49:798–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Cyranoski D: CRISPR gene-editing tested in
a person for the first time. Nature. 539:4792016. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Ran FA, Cong L, Yan WX, Scott DA,
Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, et
al: In vivo genome editing using Staphylococcus aureus Cas9.
Nature. 520:186–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Bengtsson NE, Hall JK, Odom GL, Phelps MP,
Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR and Chamberlain
JS: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates
pathophysiology in a mouse model for Duchenne muscular dystrophy.
Nat Commun. 8:144542017. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Xu C, Lu Z, Luo Y, Liu Y, Cao Z, Shen S,
Li H, Liu J, Chen K, Chen Z, et al: Targeting of NLRP3 inflammasome
with gene editing for the amelioration of inflammatory diseases.
Nat Commun. 9:40922018. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Wang YC, Liu QX, Zheng Q, Liu T, Xu XE,
Liu XH, Gao W, Bai XJ and Li ZF: Dihydromyricetin alleviates
sepsis-induced acute lung injury through inhibiting NLRP3
inflammasome-dependent pyroptosis in mice model. Inflammation.
42:1301–1310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Tang F, Fan K, Wang K and Bian C:
Amygdalin attenuates acute liver injury induced by D-galactosamine
and lipopolysaccharide by regulating the NLRP3, NF-κB and Nrf2/NQO1
signalling pathways. Biomed Pharmacother. 111:527–536. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Zhao Q, Bi Y, Guo J, Liu YX, Zhong J, Pan
LR, Tan Y and Yu XJ: Pristimerin protects against inflammation and
metabolic disorder in mice through inhibition of NLRP3 inflammasome
activation. Acta Pharmacol Sin. 42:975–986. 2021. View Article : Google Scholar :
|
|
238
|
Shi J, Xia Y, Wang H, Yi Z, Zhang R and
Zhang X: Piperlongumine Is an NLRP3 Inhibitor With
Anti-inflammatory Activity. Front Pharmacol. 12:8183262021.
View Article : Google Scholar
|
|
239
|
Zhao J, Liu H, Hong Z, Luo W, Mu W, Hou X,
Xu G, Fang Z, Ren L, Liu T, et al: Tanshinone I specifically
suppresses NLRP3 inflammasome activation by disrupting the
association of NLRP3 and ASC. Mol Med. 29:842023. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Liao T, Ding L, Wu P, Zhang L, Li X, Xu B,
Zhang H, Ma Z, Xiao Y and Wang P: Chrysin attenuates the NLRP3
inflammasome cascade to reduce synovitis and pain in KOA rats. Drug
Des Devel Ther. 14:3015–3027. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Liu B and Yu J: Anti-NLRP3 inflammasome
natural compounds: An update. Biomedicines. 9:1362021. View Article : Google Scholar : PubMed/NCBI
|
